TuHURA Biosciences, Inc./NV
TuHURA Biosciences, Inc./NV is a Nevada-based clinical-stage immuno-oncology company focused on developing therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Its pipeline centers on proprietary technologies and product candidates that are being advanced through preclinical and clinical development in the United States.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates and platforms designed to overcome resistance to cancer immunotherapies.
Early-stage discovery, laboratory work, and translational studies supporting the pipeline.
Clinical study execution, CRO management, and trial-related development activities.
Customers
TuHURA does not currently sell commercial products; its direct counterparties are research organizations, clinical investigators, contract manufacturers, and other development partners that support its pipeline. If approved in the future, its end customers would be oncology patients and the healthcare providers who prescribe cancer therapies. The business is therefore funded and advanced through capital markets and development collaborations rather than product sales.
CROs, investigators, and trial sites that execute studies and generate clinical data.
Third-party manufacturers and suppliers that produce drug substance and materials.
Equity and debt investors that fund ongoing R&D and corporate operations.
Patients who would receive approved immuno-oncology therapies if development succeeds.
Strategy
TuHURA’s strategy is to advance its immuno-oncology pipeline through preclinical and clinical development while building evidence that its technologies can address resistance to existing cancer immunotherapies. It also relies on external financing, collaborations, and licensing to fund development until a product candidate can be approved and commercialized.
Clinical and regulatory progress is the main path to future value creation.
The company needs capital to sustain R&D and public-company operations.
Additional candidates can diversify scientific and clinical risk over time.
Geography
TuHURA is incorporated in Nevada and operates primarily from the United States, where its development, financing, and regulatory activities are centered. Its business is tied to U.S. clinical development and FDA oversight, while future commercialization would also expose it to foreign pricing and supply-chain conditions if it expands internationally.
Risks
TuHURA faces the typical risks of a clinical-stage biotech company: long development timelines, regulatory uncertainty, and dependence on external capital before any product revenue exists. Its specific risks also include merger-related dilution, supply-chain and tariff exposure, and the possibility that acquired intangible assets or in-process R&D may be impaired if programs do not advance.
- No near-term product revenueImpact: CriticalLikelihood: High
The company is pre-commercial and depends on successful development and approval.
Exposure: All programs
- Clinical and regulatory failureImpact: CriticalLikelihood: Low
Drug candidates may not show sufficient safety, efficacy, or approvability.
Exposure - Financing and dilution riskImpact: HighLikelihood: High
Operations require repeated capital raises before commercialization.
Exposure - Supply-chain and tariff disruptionImpact: MediumLikelihood: Medium
Materials and manufacturing inputs may be delayed or become more expensive.
Exposure: Manufacturing and clinical supply
- Merger-related share overhangImpact: Medium
Former Kineta holders and other stockholders may sell shares after the merger.
Exposure: Common stock trading
Accounting
Judgemental itemsClinical and manufacturing invoices may arrive after services are performed, requiring estimates.
Impact: Affects operating expenses and liabilities
Equity awards to employees and consultants are a recurring non-cash expense.
Impact: Affects reported losses and dilution analysis
The Kineta merger created capitalized in-process R&D with significant measurement uncertainty.
Impact: Affects intangible assets and potential impairment charges
Goodwill from business combinations must be tested if indicators of impairment arise.
Impact: Could create large non-cash write-downs
Similar listed companies
Publicly listed companies with a comparable business focus.
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
Last updated: 24/09/2026